Sep 2026· Journal of Proteome Research· Vol 25 10, pp.
5284-5304
· 0 citations· 84 references
Medicine
TL;DR
It is shown that PRDX6 depletion enhances radiosensitivity in A549 lung cancer cells, and the underlying drivers of ferroptosis sensitivity in the PRDX6 background are identified.
Abstract
Ionizing radiation (IR) induces oxidative stress and lipid peroxidation with ferroptosis contributing to radiation-induced cancer cell death. Peroxiredoxin 6 (PRDX6), a multifunctional enzyme involved in phospholipid repair and redox regulation, has been implicated in ferroptosis regulation, but its role in the radiosensitivity of cancer cells remains unclear. Here, we show that PRDX6 depletion enhances radiosensitivity in A549 lung cancer cells. PRDX6-silenced A549 cells exhibited elevated lipid peroxidation and labile iron levels, indicating a ferroptosis-prone state that was amplified by radiation. To identify the underlying drivers of ferroptosis sensitivity in the PRDX6 background, we performed global proteomic profiling of PRDX6-silenced A549 cells, with and without radiation. Basal PRDX6-deficient cells displayed increased levels of ACSL4 and DHCR7. ACSL4 activates peroxidation-prone polyunsaturated fatty acids for incorporation into membrane phospholipids, and DHCR7 depletes the antiferroptotic moiety, 7-dehydrocholesterol. MPST, an antioxidant protein, was downregulated. These changes were accentuated upon IR exposure with further suppression of GINS4, a negative regulator of ferroptosis. Functional rescue by oleic acid suggested the role of ACSL4 in the observed phenotypes. Radiosensitization via ferroptosis induction was additionally demonstrated in another human lung cancer cell line under the PRDX6-silenced state. Collectively, PRDX6 loss remodels the cellular proteome to establish a presensitized redox and lipid compositional state, which favors ferroptosis-driven radiosensitivity.
Abstract Ferroptosis is an iron-dependent form of regulated cell death characterized by lipid peroxidation and has emerged as a promising therapeutic target in cancer. However, increasing evidence indicates that tumor cells develop adaptive mechanisms to evade ferroptosis, limiting the efficacy of ferroptosis-inducing...
Thioredoxin (TXN), a central redox regulator, is identified as a ferroptosis suppressor associated with poor prognosis in MM patients and the IRF1-TXN axis is established as a potential therapeutic target for overcoming ferroptosis resistance and improving MM treatment outcomes.
Jia-Xi Liu, Ji-Yu Miao, Yang Lv et al.· Cell Death & Disease· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer marked by oxidative stress, metabolic rewiring, and resistance to cell death. Ferroptosis, a regulated cell death driven by iron-dependent lipid peroxidation, represents a promising therapeutic vulnerability in PDAC; however, intrinsic resistance to...
M. Zivanovic, Ljubodrag Aleksić, Milica Selaković et al.· Journal of the Serbian Chemi...· 0 citations
Ferroptosis is an iron-dependent form of regulated cell death that has emerged as a potential vulnerability in cancer cells under therapeutic stress. However, the mechanisms by which colorectal cancer cells modulate ferroptosis susceptibility remain incompletely understood. In this study, we investigated the role of CW...
Kuei-Yen Tsai, Po-Li Wei, Cheng-Chin Lee et al.· International Journal of Mol...· 0 citations
Ferroptosis is implicated as a vulnerability in multiple cancers, yet approaches for effectively inducing ferroptosis in vivo are limited. Bypassing conventional strategies targeting the antiferroptotic glutathione peroxidase 4 (GPX4) and ferroptosis suppressor protein 1 (FSP1) proteins, we designed metabolic initiator...
Zi-Jian Pan, Ming-Kwan Wong, Yang Lu et al.· Cell· 1 citation
Ferroptosis is an iron-dependent form of regulated cell death driven by phospholipid peroxidation and the failure of cellular antioxidant defenses. Its close integration with iron metabolism, lipid remodeling, and redox homeostasis has identified ferroptosis as a potentially exploitable vulnerability in cancer. This re...
A. Zdanowicz, B. Pradhan, B. Pyrzyńska et al.· Pharmacological Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.